A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • Prostatic Neoplasms
  • Taxoids

abstract

  • Oral panobinostat with and without docetaxel is feasible, and docetaxel had no apparent effect on the pharmacokinetics of panobinostat. Since preclinical studies suggest a dose-dependent effect of panobinostat on PSA expression, and other phase I data demonstrate that intravenous panobinostat produces higher peak concentrations (>20- to 30-fold) and area under the curve (3.5x-5x), a decision was made to focus the development of panobinostat on the intravenous formulation to treat CRPC.

publication date

  • May 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1007/s00280-010-1289-x

PubMed ID

  • 20217089

Additional Document Info

start page

  • 181

end page

  • 9

volume

  • 66

number

  • 1